Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out

NCT ID NCT06956248

Recruiting now Knowledge-focused Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses and side effects, which could help improve future cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Off-label systemic therapies recommended by a molecular tumor board
What this could lead to: If successful, this could help standardize how we evaluate off-label treatments for advanced cancers, potentially guiding future drug development.
What could go wrong: This is a small, early observational study with only 50 participants. It does not test a new treatment directly, so results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TREATMENT REFRACTORY CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

National Cancer Centre, Singapore
RECRUITING

Singapore, 168583, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.